reMYND’s proprietary APPxTAU model is combining the progressive amyloidosis and tau-o-pathies modeled by the respective single transgenics, and as such modeling a combined, progressive Abeta and tau pathology.

To introduce tau pathology in the APP-London mouse, the bigenic APP[V717I]xTAU[P301L] mouse line (APP-ldxTAU.P301L) was created. Three important characteristics of Alzheimer’s disease are recapitulated in this model: intracellular neurofibrillary tangles (NFTs), extracellular amyloid plaques and cognitive impairment. The bigenic APPxTAU model allows to assess the effects of your Alzheimer treatment on both amyloid- and tau pathology in the same model.